



Daftar Pustaka

- AIRTUM Working Group, CCM, AIEOP Working Group. *Italian cancer figures, report 2012: Cancer In Children And Adolescents*. Epidemiol Prev n.d.;37:1–225.
- Beau-Faller M, Prim N, Ruppert A-M, Nanni-Metéllus I, Lacave R, Lacroix L, et al. *Rare EGFR Exon 18 And Exon 20 Mutations In Non-Small-Cell Lung Cancer On 10 117 Patients: A Multicentre Observational Study By The French ERMETIC-IFCT Network*. Ann Oncol 2014;25:126–31. doi:10.1093/annonc/mdt418.
- Bhattacharyya N. *A Population-Based Analysis Of Survival Factors In Differentiated And Medullary Thyroid Carcinoma*. Otolaryngol Head Neck Surg 2003;128:115–23. doi:10.1067/mhn.2003.2
- Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F. *Prognostic And Predictive Value Of EGFR In Head And Neck Squamous Cell Carcinoma*. Oncotarget 2016;7:74362–79. doi:10.18632/oncotarget.11413.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. *Global Cancer Statistics 2018: GLOBOCAN Estimates Of Incidence And Mortality Worldwide For 36 Cancers In 185 Countries*. CA Cancer J Clin 2018;68:394–424. doi:10.3322/caac.21492.
- Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. *The Risk Of Second Primary Malignancies Up To Three Decades After The Treatment Of Differentiated Thyroid Cancer*. J Clin Endocrinol Metab 2008;93:504–15. doi:10.1210/jc.2007-1154.
- Calvo, E. and Baselga, J. (2006) ‘Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’, *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 24, pp. 2158–63. doi: 10.1200/JCO.2006.06.5961.



Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. *Revised American*

Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2009;19:1167–214. doi:10.1089/thy.2009.0110.

Deng, Y. *et al.* (2020) ‘Global Burden of Thyroid Cancer From 1990 to 2017’, *JAMA Network Open*, 3(6), p. e208759. doi: 10.1001/jamanetworkopen.2020.8759.

Dai Y-J, Qiu Y-B, Jiang R, Xu M, Zhao L, Chen GG, et al. *Concomitant High Expression Of Era36, EGFR And HER2 Is Associated With Aggressive Behaviors Of Papillary Thyroid Carcinomas.* *Sci Rep* 2017;7:12279. doi:10.1038/s41598-017-12478-1.

De Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, et al. *The Percentage Of Epidermal Growth Factor Receptor (EGFR)-Mutated Neoplastic Cells Correlates To Response To Tyrosine Kinase Inhibitors In Lung Adenocarcinoma.* *PLoS One* 2017;12:e0177822. doi:10.1371/journal.pone.0177822.

Fallahi, P. *et al.* (2020) ‘Molecular targets of tyrosine kinase inhibitors in thyroid cancer’, *Seminars in Cancer Biology*, p. S1044579X20302492. doi: 10.1016/j.semcancer.2020.11.013.

Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, et al. *Epidermal Growth Factor Receptor Overexpression Is A Marker For Adverse Pathologic Features In Papillary Thyroid Carcinoma.* *J Surg Res* 2013;185:217–24. doi:10.1016/j.jss.2013.05.003.

Gawin, M. *et al.* (2019) ‘Molecular Heterogeneity of Papillary Thyroid Cancer: Comparison of Primary Tumors and Synchronous Metastases in Regional Lymph Nodes by Mass Spectrometry Imaging’, *Endocrine Pathology*, 30(4), pp. 250–261. doi: 10.1007/s12022-019-09593-2.



- Galuppini F, Pennelli G, Rugge M. *The Rising Incidence Of Papillary Thyroid Cancer: More Cancers Or More Assessments?* Indian J Cancer 2019;56:183–4. doi:10.4103/ijc.IJC_483_18.
- Goodarzi, Moslem A, Feizhadad H, Jarrahi AM, Adineh HA, Sohrabivafa M, et al. *Epidemiology, Incidence And Mortality Of Thyroid Cancer And Their Relationship With The Human Development Index In The World: An Ecology Study In 2018.* Adv Hum Biol 2019;9:162. doi:10.4103/AIHB.AIHB_2_19.
- Hartmann JT, Haap M, Kopp H-G, Lipp H-P. *Tyrosine Kinase Inhibitors - A Review On Pharmacology, Metabolism And Side Effects.* Curr Drug Metab 2009;10:470–81.
- Haugen Bryan R, Alexander Erik K, Bible Keith C, Doherty Gerard M, Mandel Susan J, Nikiforov Yuri E, FurioPacini, Randolph Gregory W, Sawka Anna M, Schlumberger Martin, Schuff KathrynG., Sherman Steven I, Sosa Julie Ann, Steward David L, Tuttle R. Michael, Wartofsky Leonard. 2015 America Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. THYROID Volume 26, Number 11, 2016. doi: 10.1089/thy.2015.0020.
- Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, et al. *HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells.* Cancer Res 2005;65:4253–60. doi:10.1158/0008-5472.CAN-04-2748.
- Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, et al. *Zd1839 (Iressa) Induces Antiangiogenic Effects Through Inhibition Of Epidermal Growth Factor Receptor Tyrosine Kinase.* Cancer Res 2002;62:2554–60.



Huang S-F, Cheng S-D, Chien H-T, Liao C-T, Chen I-H, Wang H-M, et al. *Relationship*

Between Epidermal Growth Factor Receptor Gene Copy Number And Protein

Expression In Oral Cavity Squamous Cell Carcinoma. Oral Oncol 2012;48:67–72.

doi:10.1016/j.oraloncology.2011.06.511.

Huang S-F, Chien H-T, Cheng S-D, Chuang W-Y, Liao C-T, Wang H-M. *EGFR Copy Number*

Alterations In Primary Tumors, Metastatic Lymph Nodes, And Recurrent And

Multiple Primary Tumors In Oral Cavity Squamous Cell Carcinoma. BMC Cancer

2017;17. doi:10.1186/S12885-017-3586-9.

Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. *The Most Commonly*

Occurring Papillary Thyroid Cancer in the United States Is Now a

Microcarcinoma in a Patient Older than 45 Years. Thyroid 2011;21:231–6.

doi:10.1089/thy.2010.0137.

Hynes, N. E. and MacDonald, G. (2009) ‘ErbB receptors and signaling pathways in cancer’,

Current Opinion in Cell Biology, 21(2), pp. 177–184. doi:

10.1016/j.ceb.2008.12.010.

Išić Denčić T, Bartolome A, Šelemetjev S, Đorić I, Tatić S, Živaljević V, et al. *High Expression*

And Localization Of B-Catenin And Epidermal Growth Factor Receptor Identify

High Risk Papillary Thyroid Carcinoma Patients. Exp Mol Pathol 2018;105:181–

9. doi:10.1016/j.yexmp. 2018.08.001.

Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, et al. *Gender Is An*

Age-Specific Effect Modifier For Papillary Cancers Of The Thyroid Gland. Cancer

Epidemiol Biomarkers Prev 2009;18:1092–100. doi:10.1158/1055-9965.EPI-08-

0976.



Kim S, Kim H-R, Kim C, Koh J, Baek H, Choi C-M, et al. *Association Between Thyroid Cancer And Epidermal Growth Factor Receptor Mutation In Female With Nonsmall Cell Lung Cancer*. *Ann Thorac Med* 2017;12:36. doi:10.4103/1817-1737.197774.

Konturek A, Barczyński M, Nowak W, Richter P. *Prognostic Factors In Differentiated Thyroid Cancer - A 20-Year Surgical Outcome Study*. *Langenbeck's Arch Surg* 2012;397:809–15. doi:10.1007/s00423-011-0899-z.

Krassas GE, Pontikides N. *Gonadal Effect Of Radiation From 131I In Male Patients With Thyroid Carcinoma*. *Arch Androl* n.d.;51:171–5.

Landriscina, M. *et al.* (2011) 'Epidermal Growth Factor Receptor 1 Expression Is Upregulated in Undifferentiated Thyroid Carcinomas in Humans', *Thyroid*, 21(11), pp. 1227–1234. doi: 10.1089/thy.2011.0172.

La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. *Thyroid Cancer Mortality And Incidence: A Global Overview*. *Int J Cancer* 2015;136:2187–95. doi:10.1002/ijc.29251.

Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. *Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma*. *J Clin Endocrinol Metab* 2007;92:4085–90. doi:10.1210/jc.2007-1179.

Mao Y, Xing M. *Recent Incidences And Differential Trends Of Thyroid Cancer In The USA*. *Endocr Relat Cancer* 2016;23:313–22. doi:10.1530/ERC-15-0445.

Masago, K. *et al.* (2009) 'Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma', *International Journal of Cancer*, 124(11), pp. 2744–2749. doi: 10.1002/ijc.24250.

Mitsiades, C. S. *et al.* (2006) 'Epidermal Growth Factor Receptor as a Therapeutic Target in Human Thyroid Carcinoma: Mutational and Functional Analysis', *The Journal of*



- Clinical Endocrinology & Metabolism*, 91(9), pp. 3662–3666. doi: 10.1210/jc.2006-0055.
- McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. *Anaplastic Thyroid Carcinoma: A 50-Year Experience At A Single Institution*. *Surgery* 2001;130:1028–34. doi:10.1067/msy.2001.118266.
- McLeod DS, Sawka AM, Cooper DS. *Controversies In Primary Treatment Of Low-Risk Papillary Thyroid Cancer*. *Lancet* 2013;381:1046–57. doi:10.1016/S0140-6736(12)62205-3.
- Murugan, A. K. et al. (2011) ‘Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers’, *Endocrine Pathology*, 22(2), pp. 97–102. doi: 10.1007/s12022-011-9155-x.
- Omran OM. *EGFR and CXCR1 expression in thyroid carcinoma in Qassim Region-Saudi Arabia: Correlation with clinicopathological parameters*. *Pathophysiology* 2019;26:145–51. doi:10.1016/j.pathophys.2019.04.003.
- Patel A, Jhiang S, Dogra S, Terrell R, Powers PA, Fenton C, et al. *Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have A Lower Risk Of Recurrence For Children And Adolescents*. *Pediatr Res* 2002;52:737–44. doi:10.1203/00006450-200211000-00021.
- Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. *Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors*. *J Cancer Epidemiol* 2013;2013:1–10. doi:10.1155/2013/965212.
- Rahbari R, Zhang L, Kebebew E. *Thyroid Cancer Gender Disparity*. *Futur Oncol* 2010;6:1771–9. doi:10.2217/fon.10.127.
- Ramlau R, Krawczyk P, Dziadziuszko R, Chmielewska I, Milanowski J, Olszewski W, et al. *Predictors Of EGFR Mutation And Factors Associated With Clinical Tumor Stage*



- At Diagnosis: Experience Of The INSIGHT Study In Poland.* *Oncol Lett* 2017;14:5611–8. doi:10.3892/ol.2017.6907.
- Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams K, Kyzas PA, et al. *Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research.* *PLoS Med* 2013;10. doi:10.1371/journal.pmed.1001380.
- Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, et al. *Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer.* *Clin Cancer Res* 2004;10:8594–602. doi:10.1158/1078-0432.CCR-04-0690.
- Schlessinger J. *Cell Signaling By Receptor Tyrosine Kinases.* *Cell* 2000;103:211–25. doi:10.1016/s0092-8674(00)00114-8.
- Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, Maini CL. *Natural History And Clinical Outcome Of Differentiated Thyroid Carcinoma: A Retrospective Analysis Of 1503 Patients Treated At A Single Institution.* *Ann Oncol Off J Eur Soc Med Oncol* 2009;20:1728–35. doi:10.1093/annonc/mdp050.
- Shaha AR, Shah JP, Loree TR. *Risk Group Stratification And Prognostic Factors In Papillary Carcinoma Of Thyroid.* *Ann Surg Oncol* 1996;3:534–8.
- Sharma A, Jasim S, Reading CC, Ristow KM, Villasboas Bisneto JC, Habermann TM, et al. *Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study.* *Thyroid* 2016;26:1061–7. doi:10.1089/thy.2016.0095.
- Siegel RL, Miller KD, Jemal A. *Cancer statistics of American 2019.* *CA Cancer J Clin* 2019. doi:10.3322/caac.21551.
- Sigismund, S., Avanzato, D., & Lanzetti, L. (2017). *Emerging functions of the EGFR in cancer.* *Molecular Oncology*, 12(1), 3–20. doi:10.1002/1878-0261.12155



- Sipos, J. A. and Mazzaferri, E. L. (2010) ‘Thyroid cancer epidemiology and prognostic variables’, *Clinical Oncology (Royal College of Radiologists (Great Britain))*, 22(6), pp. 395–404. doi: 10.1016/j.clon.2010.05.004.
- Smallridge Robert C, Ain Kenneth B, Asa Sylvia L, Bible Keith C, Brierly James D, Burman Kenneth D, Kebebew Electron, Lee Nancy Y, Nikiforov Yuri E, Rosenthal M Sara, Shahn Manisha H, Shaha Ashok R, Tuttle R Michael, et al. American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. *THYROID* Volume 22, Number 11, 2012. doi: 10.1089/thy.2012.0302.
- Souza Rosário PW, Alvarenga Fagundes T, Villas-Boas Fagundes AS, Barroso AL, Lamego Rezende L, Lanza Padrão E, et al. *Ovarian Function After Radioiodine Therapy In Patients With Thyroid Cancer*. *Exp Clin Endocrinol Diabetes* 2005;113:331–3. doi:10.1055/s-2005-837666.
- Sun P-L, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. *High Incidence Of EGFR Mutations In Korean Men Smokers With No Intratumoral Heterogeneity Of Lung Adenocarcinomas: Correlation With Histologic Subtypes, EGFR/TTF-1 Expressions, And Clinical Features*. *J Thorac Oncol* 2012;7:323–30. doi:10.1097/JTO.0b013e3182381515.
- Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, et al. *Clinicopathologic Characteristics Of The EGFR Gene Mutation In Non-Small Cell Lung Cancer*. *J Thorac Oncol* 2006;1:231–9.
- Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, et al. *Radioactive Iodine Administered for Thyroid Remnant Ablation Following Recombinant Human Thyroid Stimulating Hormone Preparation Also Has an Important Adjuvant Therapy Function*. *Thyroid* 2010;20:257–63. doi:10.1089/thy.2009.0401.



Vuong HG, Kondo T, Duong UNP, Pham TQ, Oishi N, Mochizuki K, et al. *Prognostic Impact*

Of Vascular Invasion In Differentiated Thyroid Carcinoma: A Systematic Review

And Meta-Analysis. Eur J Endocrinol 2017;177:207–16. doi:10.1530/EJE-17-

0260.

Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, et al. *Growth*

Factor Receptor Expression In Anal Squamous Lesions: Modifications Associated

With Oncogenic Human Papillomavirus And Human Immunodeficiency Virus.

Hum Pathol 2009;40:1517–27. doi:10.1016/j.humpath.2009.05.010.

Wells Samuel A. Jr., Asa Slyvia L, Dralle Hening, Elisei Rossella, Evans Douglas B, Gagel

Robert F, Nancy Lee, Machens Andreas, Moley Jeffrey F, Pacini Furio, Raue

Friedhelm, Frank-Raue Karin, Robinson Bruce, Rosenthal M. Sara, Sanoro

Massimo, Schlumberger Martin, Manisha Shah, Waguespack Steven G. Revised

American Thyroid Association Guidelines for the Management of Meddulary

Thyroid Carcinoma. 2015. The American Thyroid Association Guidelines Task

Force on Medullary Thyroid Carcinoma. doi :10.1089.

WHO. *World Health Organization Classification of Tumours : Pathology and Genetics of*

Tumours of Endocrine Organs 2004:50–2.